Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience

Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience

The adoption of neoadjuvant chemotherapy (NACT) for breast cancer (BC) is increasing. The need to repeat the biomarkers on a residual tumor after NACT is still a matter of debate. We verified estrogen receptors (ER), progesterone receptors (PR), Ki67 and human epidermal growth factor receptor 2 (HER...

Full description

Bibliographic Details
Main Authors: Saverio Coiro, Elisa Gasparini, Giuseppe Falco, Giacomo Santandrea, Moira Foroni, Giulia Besutti, Valentina Iotti, Roberto Di Cicilia, Monica Foroni, Simone Mele, Guglielmo Ferrari, Giancarlo Bisagni, Moira Ragazzi
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Diagnostics
Subjects:
ER
HER2
PR
ki67
breast cancer
immunohistochemistry
Online Access:https://www.mdpi.com/2075-4418/11/12/2249

Internet

https://www.mdpi.com/2075-4418/11/12/2249

Similar Items